Skip to main content

Table 2 Patient characteristics and doses given in each subject, cohort, and cycle

From: Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome

Cohort Subject number Sex/age WHO diagnosis Donor GVHD gradea Cycle (mg/m2/day for 5 days)
Acute Chronic 1 2 3 4
1 1 F/19 RAEB-2 MSD 0 0 5b,c 1.5 1.5 1.5
2 M/36 AML MSD 0 0 5b 6 5.5 6
3 M/60 RAEB-2 MUD 1 0 5
4 M/48 AML MSD 0 0 5b,c 1.5 2.5 3
2 5 M/64 RAEB-2 PMUD 1 0 4b 4 5.5 7
6 F/43 RAEB-2 MSD 0 0 4b 7 8 12
7 M/64 AML MSD 0 0 4b 6 5.5 5.5
3 8 F/51 RAEB-2 MUD 1 0 5b 7.5b,c 7.5c 7
9 F/59 RAEB-1 MUD 2 0 5b,c 3.5 4 4.5
10 F/36 RAEB-2 MUD 1 0 5b 6b 8.5 9
4 11 M/64 RAEB-2 MSD 2 0 5.5b 2b
12 M/60 RAEB-2 MSD 0 Mild 5.5b,c 4.5b 7 8
13 M/41 RAEB-2 MSD 0 0 5.5b,c 3 5 8
5 14 M/49 AML MUD 2 0 5b 1.5 2.5 3
15 F/50 AML MSD 2 0 5b,c 4 6 9
16 F/49 RAEB-2 MSD 2 0 5b 7.5 8 11c
  1. GVHD graft-versus-host disease, RAEB refractory anemia with excess blast, MSD matched sibling donor, PMUD partially matched unrelated donor, MUD matched unrelated donor
  2. aAssessed at the time of decitabine initiation
  3. bIndividual dose titration (IDT) by the PK-PD model was not applied
  4. cThe cycles where grade 4 toxicities occurred